Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 17/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21887465 | 1.00 | MAP3K5 (0.47) | MAP3K5MAPTDDB1CRBN | |
| SCHEMBL25316841 | 0.82 | MAP3K5 (0.47) | MAP3K5DDB1CRBN | |
| SCHEMBL30352583 | 0.82 | MAP3K5 (0.47) | MAP3K5DDB1CRBN | |
| SCHEMBL28648093 | 0.80 | MAP3K5 (0.52) | MAP3K5 | |
| SCHEMBL28848714 | 0.79 | MAP3K5 (0.42) | MAP3K5 | |
| SCHEMBL28848739 | 0.79 | MAP3K5 (0.38) | MAP3K5 | |
| SCHEMBL29949305 | 0.79 | MAP3K5 (0.38) | MAP3K5 | |
| SCHEMBL23510668 | 0.78 | MAP3K5 (0.45) | MAP3K5 | |
| SCHEMBL23510667 | 0.78 | MAP3K5 (0.46) | MAP3K5 | |
| SCHEMBL27959304 | 0.77 | MAP3K5 (0.52) | MAP3K5MAPTDDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220056019-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. | 2022-02-24 | — | — | US | disclosed |
| US-20220054469-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220056019-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | MAP3K5 2258/4885MAPT 4394/4885DDB1 2363/4885 |
| US-20220054469-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | MAP3K5 2258/4885MAPT 4394/4885DDB1 2363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.